Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5396-404. doi: 10.1016/j.bmcl.2012.07.052. Epub 2012 Jul 21.

Abstract

With structural guidance, tropane-derived HTS hits were modified to optimize for HSP90 inhibition and a desirable in vivo profile. Through an iterative SAR development process 12i (XL888) was discovered and shown to reduce HSP90 client protein content in PD studies. Furthermore, efficacy experiments performed in a NCI-N87 mouse xenograft model demonstrated tumor regression in some dosing regimens.

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Azabicyclo Compounds / chemistry*
  • Azabicyclo Compounds / pharmacokinetics
  • Azabicyclo Compounds / pharmacology
  • Azabicyclo Compounds / therapeutic use*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Crystallography, X-Ray
  • Drug Discovery
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • HSP90 Heat-Shock Proteins / metabolism
  • Humans
  • Mice
  • Models, Molecular
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Phthalic Acids / chemistry*
  • Phthalic Acids / pharmacokinetics
  • Phthalic Acids / pharmacology
  • Phthalic Acids / therapeutic use*

Substances

  • Antineoplastic Agents
  • Azabicyclo Compounds
  • HSP90 Heat-Shock Proteins
  • Phthalic Acids
  • XL 888